Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study

類似資料

• Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
  著者:: Gooderham, Melinda, 等
  出版事項: (2015)
• Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
  著者:: Kavanaugh, Arthur, 等
  出版事項: (2014)
• Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
  著者:: Ohtsuki, Mamitaro, 等
  出版事項: (2017)
• Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient‐reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials
  著者:: Thaçi, D., 等
  出版事項: (2016)
• Oral Apremilast for the Treatment of Plaque Psoriasis
  著者:: Del Rosso, James Q., 等
  出版事項: (2016)